Covalent inhibitors design and discovery

被引：234

作者：

De Cesco, Stephane ^{[1
]}

Kurian, Jerry ^{[1
]}

Dufresne, Caroline ^{[1
]}

Mittermaier, Anthony K. ^{[1
]}

Moitessier, Nicolas ^{[1
]}

机构：

[1] McGill Univ, Dept Chem, 801 Sherbrooke St W, Montreal, PQ H3A 0B8, Canada

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2017年 / 138卷

关键词：

Covalent drugs; Drug design; Binding kinetics; Docking; TARGET RESIDENCE TIME; ACETYLGLUCOSAMINE ENOLPYRUVYL TRANSFERASE; UDP-N-ACETYLGLUCOSAMINE; DIPEPTIDYL PEPTIDASE-IV; ERBB FAMILY BLOCKER; DRUG DISCOVERY; KINASE INHIBITORS; NATURAL-PRODUCTS; IRREVERSIBLE INHIBITORS; ALKYLATING-AGENTS;

D O I：

10.1016/j.ejmech.2017.06.019

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In the history of therapeutics, covalent drugs occupy a very distinct category. While representing a significant fraction of the drugs on the. market, very few have been deliberately designed to interact covalently with their biological target. In this review, the prevalence of covalent drugs will first be briefly covered, followed by an introduction to their mechanisms of action and more detailed discussions of their discovery and the development of safe and efficient covalent enzyme inhibitors. All stages of a drug discovery program will be covered, from target considerations to lead optimization, strategies to tune reactivity and computational methods. The goal of this article is to provide an overview of the field and to outline good practices that are needed for the proper assessment and development of covalent inhibitors as well as a good understanding of the potential and limitations of current computational methods for the design of covalent drugs. (C) 2017 Elsevier Masson SAS. All rights reserved.

引用

页码：96 / 114

页数：19

共 126 条

[31] Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270 [J].

Ding, ZR ;

Kim, S ;

Dorsam, RT ;

Jin, JG ;

Kunapuli, SP .

BLOOD, 2003, 101 (10) :3908-3914

[32] Protein-reactive natural products [J].

Drahl, C ;

Cravatt, BF ;

Sorensen, EJ .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2005, 44 (36) :5788-5809

[33] Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release [J].

Eschenburg, S ;

Priestman, M ;

Schönbrunn, E .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (05) :3757-3763

[34] Bacterial resistance to β-lactam antibiotics:: Compelling opportunism, compelling opportunity [J].

Fisher, JF ;

Meroueh, SO ;

Mobashery, S .

CHEMICAL REVIEWS, 2005, 105 (02) :395-424

[35] Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors [J].

Flanagan, Mark E. ;

Abramite, Joseph A. ;

Anderson, Dennis P. ;

Aulabaugh, Ann ;

Dahal, Upendra P. ;

Gilbert, Adam M. ;

Li, Chao ;

Montgomery, Justin ;

Oppenheimer, Stacey R. ;

Ryder, Tim ;

Schuff, Brandon P. ;

Uccello, Daniel P. ;

Walker, Gregory S. ;

Wu, Yan ;

Brown, Matthew F. ;

Chen, Jinshan M. ;

Hayward, Matthew M. ;

Noe, Mark C. ;

Obach, R. Scott ;

Philippe, Laurence ;

Shanmugasundaram, Veerabahu ;

Shapiro, Michael J. ;

Starr, Jeremy ;

Stroh, Justin ;

Che, Ye .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (23) :10072-10079

[36] Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore [J].

Fleming, Fraser F. ;

Yao, Lihua ;

Ravikumar, P. C. ;

Funk, Lee ;

Shook, Brian C. .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (22) :7902-7917

[37] The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K [J].

Gauthier, Jacques Yves ;

Chauret, Nathalie ;

Cromlish, Wanda ;

Desmarais, Sylvie ;

Duong, Le T. ;

Falgueyret, Jean-Pierre ;

Kimmel, Donald B. ;

Lamontagne, Sonia ;

Leger, Serge ;

LeRiche, Tammy ;

Li, Chun Sing ;

Masse, Frederic ;

Mckay, Daniel J. ;

Nicoll-Griffith, Deborah A. ;

Oballa, Renata A. ;

Palmer, James T. ;

Percival, M. David ;

Riendeau, Denis ;

Robichaud, Joel ;

Rodan, Gideon A. ;

Rodan, Sevgi B. ;

Seto, Carmai ;

Therien, Michel ;

Truong, Vouy-Linh ;

Venuti, Michael C. ;

Wesolowski, Gregg ;

Young, Robert N. ;

Zamboni, Robert ;

Black, W. Cameron .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (03) :923-928

[38] The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro [J].

Gee, JMW ;

Harper, ME ;

Hutcheson, IR ;

Madden, TA ;

Barrow, D ;

Knowlden, JM ;

McClelland, RA ;

Jordan, N ;

Wakeling, AE ;

Nicholson, RI .

ENDOCRINOLOGY, 2003, 144 (11) :5105-5117

[39] Electrophilic natural products and their biological targets [J].

Gersch, Malte ;

Kreuzer, Johannes ;

Sieber, Stephan A. .

NATURAL PRODUCT REPORTS, 2012, 29 (06) :659-682

[40] Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol [J].

Goedken, Eric R. ;

Argiriadi, Maria A. ;

Banach, David L. ;

Fiamengo, Bryan A. ;

Foley, Sage E. ;

Frank, Kristine E. ;

George, Jonathan S. ;

Harris, Christopher M. ;

Hobson, Adrian D. ;

Ihle, David C. ;

Marcotte, Douglas ;

Merta, Philip J. ;

Michalak, Mark E. ;

Murdock, Sara E. ;

Tomlinson, Medha J. ;

Voss, Jeffrey W. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (08) :4573-4589

← 1 2 3 4 5 6 7 8 9 10 →